Skip to main content
NewslettersWatchlist

Biolinerx Ltd ADR(BLRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.6145
Day High0.6230
Open:0.6193
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
AllPennyStocks.com
New Collaboration Could Revolutionize Treatment of Chronic Spinal Cord Injuries
PR Newswire
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
PR Newswire
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer
PR Newswire
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
PR Newswire
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide
PR Newswire
BioLineRx to Report First Quarter 2023 Results on May 24, 2023
PR Newswire
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma
PR Newswire
BioLineRx to Report 2022 Annual Financial Results on March 22, 2023
Business Wire
BLRX FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm – BLRX
PR Newswire
BLRX MONDAY DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX
Business Wire
BIOLINERX DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioLineRx Ltd. and Encourages Investors to Contact the Firm
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd. (BLRX)
PR Newswire
BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit
PR Newswire
BLRX IMPORTANT DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by the Firm - BLRX
PR Newswire
BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX
PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX
PR Newswire
BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX
PR Newswire
ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX
PR Newswire
BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX
PR Newswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX
PR Newswire
BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX
PR Newswire
BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit
PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX
PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX
Business Wire
BioLineRx Ltd. (BLRX) Shareholder Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against BioLineRx Ltd.
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX
PR Newswire
BLRX Investors Have Opportunity to Lead BioLineRx Ltd. Securities Fraud Lawsuit

Profile

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.